FSD Pharma Investments Pay Off Amid ‘Robust Expansion’ at Ontario Facility
May 8th, 2019
App, Exclusive, News, Top News
- FSD Pharma’s strategic investment portfolio valued at $18 million after a market-to-market unrealized gain of $10 million.
- Management remains tightly focused on ’robust expansion’ plan at its Cobourg, Ontario facility under the leadership of Dr. Sara May.
- Balance sheet includes $22 million in cash, as of December 31, 2018, with total net assets in excess of $50 million with no long-term liabilities.
- New auditing firm hired ahead of listing on the New York Stock Exchange.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSSDF) reported its fourth quarter financial results following a major year of accomplishments. Based in Cobourg, Ontario, the company’s massive former Kraft Foods facility sits on 72 acres of land with nearly four million sq. ft. of expansion capacity. Management projects that the facility could generate upwards of 400 million grams of dried cannabis flower per year at full capacity.
The company secured both cultivation and sales licenses for the facility earlier this year, which has opened up the door to ‘robust expansion’ opportunities. In partnership with tenants, like Canntab Therapeutics Ltd. (CSE: PILL), the company leases manufacturing space in exchange for a royalty on sales and rights to the Canadian market. This business model limits its capital expenditures and could generate high margin revenue.
The company’s other partnerships include World-Class Extractions, a cannabis extraction company, and Pharmastrip Corp., a developer of cannabis-infused oral thin film strips.
“After receiving the sales license for medicinal cannabis in April 2019, we are tightly focused on developing a robust expansion plan at our Cobourg, Ontario facility under the leadership of Dr. Sara May,” said Executive Chairman and CEO Dr. Raza Bokhari in the company’s recent press release announcing its fourth quarter results. “Finalizing the next phase of expansion, with drawings, a construction budget and timeline is our top priority.”
Growing Investment Portfolio
FSD Pharma recorded a $10 million unrealized gain on its strategic investment portfolio, which includes companies like Solarvest Inc. (TSX-V: SVS). These strategic investments don’t necessarily generate top-line revenue or bottom-line profits on its financial statements, but help bolster its balance sheet with assets that provide investors with greater diversification than other companies focused exclusively on cultivation or retail.
Earlier this month, the company announced a definitive collaborative research and development agreement with Solarvest. The agreements stipulates that Solarvest will conduct research using its algae-based expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma has the option to enter into an exclusive license agreement over a subset of the project and receive royalty rights over all the products that result.
“At FSD Pharma, we continue to explore new areas of science and are committed to identifying novel cannabis cultivation methods for medical purposes,” said Dr. Raza Bokhari. “If successful, these alternative methods could dramatically disrupt current cannabis cultivation methods for medical purposes. That, and the potential to create significant value for our shareholders, is something we are very excited about.”
The company’s other strategic investments include Cannara, an aspiring licensed producer in Quebec, SciCann Therapeutics, a specialty pharmaceutical company, and High Tide Inc., a developer of lifestyle products.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSSDF) stands at a pivotal point in its corporate history. After receiving a sales license, the company can begin generating revenue over the near-term using a business model that could provide strong diversification and high margins. The company’s strategic investment portfolio also contains several moon-shot concepts that could drive significant long-term shareholder value if successful.
In addition to these catalysts, the company continues to make progress in listing its shares on the New York Stock Exchange (NYSE), which could open the door to greater liquidity.
For more information, visit the company’s website at www.fsdpharma.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.